Publications by authors named "Javier Oesterheld"

Claim this Profile
N
Naxitamab-combination Therapy for the Treatment of Patients With Refractory and/or Relapsed High-risk Neuroblastoma.
Erin Murphy Trovillion, Meghan Michael, Lauren Brown, Katlin Phillips, Javier Oesterheld

J Pediatr Hematol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trial.
Jessica Hochberg, Javier Oesterheld, Aliza Gardenswartz, Allyson Flower, Liana Klejmont

EClinicalMedicine· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation.
Aditi Dhir, Masanori Hayashi, Avery Bodlak, Javier Oesterheld, David M Loeb

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells.
Kaitlyn H Smith, Erin M Trovillion, Chloe Sholler, Divya Gandra, Kimberly Q McKinney, Javier Oesterheld

Cancers (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Giselle L Saulnier Sholler, Genevieve Bergendahl, Elizabeth C Lewis, Jacqueline Kraveka, William Ferguson, Javier Oesterheld

Genome Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital.
Erin Murphy Trovillion, Meghan Michael, Cathryn C Jordan, Lauren Brown, Katlin Phillips, Javier Oesterheld

Cancer Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Javier Oesterheld, William Ferguson, Jacqueline M Kraveka, Genevieve Bergendahl, Thomas Clinch

J Clin Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
Jacqueline M Kraveka, Elizabeth C Lewis, Genevieve Bergendahl, William Ferguson, Javier Oesterheld

Cancer Rep (Hoboken)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney.
Serena Y Tan, Alyaa Al-Ibraheemi, William A Ahrens, Javier E Oesterheld, Julie C Fanburg-Smith

Histopathology· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.
Sara A Byron, William P D Hendricks, Abhinav B Nagulapally, Jacqueline M Kraveka, William S Ferguson, Javier E Oesterheld

Cancer Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.
Stan Goldman, Matthew Barth, Bruce Shiramizu, Qiuhu Shi, Jessica Hochberg, Javier Oesterheld

Leukemia· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.
Elizabeth C Lewis, Jacqueline M Kraveka, William Ferguson, Don Eslin, Valerie I Brown, Javier Oesterheld

Int J Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation.
Javier E Oesterheld, Damon R Reed, Bhuvana A Setty, Michael S Isakoff, Patrick Thompson

Pediatr Blood Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Michael J Burke, Rumen Kostadinov, Richard Sposto, Lia Gore, Shannon M Kelley, Javier E Oesterheld

Clin Cancer Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
Weili Sun, Jemily Malvar, Richard Sposto, Anupam Verma, Jennifer J Wilkes, Javier Oesterheld

Leukemia· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance DFMO Increases Survival in High Risk Neuroblastoma.
Giselle L Saulnier Sholler, William Ferguson, Genevieve Bergendahl, Jeffrey P Bond, Kathleen Neville, Javier Oesterheld

Sci Rep· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusion.
Mark Rosenzweig, Siraj M Ali, Victor Wong, Alexa B Schrock, Theodore W Laetsch, Javier Oesterheld

Pediatr Blood Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia.
Yoav Messinger, Jessica Boklan, John Goldberg, Steven G DuBois, Javier Oesterheld

Pediatr Hematol Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Todd M Cooper, Jeannette Cassar, Elena Eckroth, Jemily Malvar, Richard Sposto, Javier Oesterheld

Clin Cancer Res· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.
Don W Coulter, Christine Walko, Jai Patel, Billie M Moats-Staats, Andrew McFadden, Javier Oesterheld

Anticancer Drugs· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis